Methodological approaches to evaluate the impact of FDA drug safety communications.
Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J.
Kesselheim AS, et al. Among authors: dal pan gj.
Drug Saf. 2015 Jun;38(6):565-75. doi: 10.1007/s40264-015-0291-y.
Drug Saf. 2015.
PMID: 25968811